Multicenter, Randomized, Double-Blind Phase Ii Study of Sorafenib Compared to Placebo with Best Supportive Care After Failure of Docetaxel in Metastatic Castration-Resistant Prostate Cancer

Annals of Oncology ◽

10.1093/annonc/mdu336.21 ◽

2014 ◽

Vol 25 ◽

pp. iv266

Author(s):

G. Kramer ◽

A. Maj-Hes ◽

A. Hobisch ◽

S.F. Shariat ◽

W. Loidl

Keyword(s):

Prostate Cancer ◽

Supportive Care ◽

Phase Ii ◽

Phase Ii Study ◽

Best Supportive Care ◽

Castration Resistant Prostate Cancer ◽

Double Blind ◽

Castration Resistant

Download Full-text

An open label phase I/randomised, double-blind phase II study in metastatic castration resistant Prostate Cancer of AZD5363 in combination with Docetaxel and prednisolone chemotherapy (ProCAID)

http://isrctn.org/> ◽

10.1186/isrctn69139368 ◽

2014 ◽

Author(s):

Study Coordinator

Keyword(s):

Prostate Cancer ◽

Phase I ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant Prostate Cancer ◽

Open Label ◽

Double Blind ◽

Castration Resistant ◽

Open Label Phase

Download Full-text

A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy

Annals of Oncology ◽

10.1093/annonc/mdx487 ◽

2017 ◽

Vol 28 (11) ◽

pp. 2741-2746 ◽

Cited By ~ 7

Author(s):

K. Fizazi ◽

A. Ulys ◽

L. Sengeløv ◽

M. Moe ◽

S. Ladoire ◽

...

Keyword(s):

Prostate Cancer ◽

Maintenance Therapy ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant Prostate Cancer ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant ◽

Docetaxel Chemotherapy

Download Full-text

Faculty Opinions recommendation of Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718242837.793489809 ◽

2014 ◽

Author(s):

Joan Hester

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant Prostate Cancer ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant ◽

Radium 223

Download Full-text

Two-Year Survival Follow-Up of the Randomized, Double-Blind, Placebo-Controlled Phase II Study of Radium-223 Chloride in Patients With Castration-Resistant Prostate Cancer and Bone Metastases

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2012.07.002 ◽

2013 ◽

Vol 11 (1) ◽

pp. 20-26 ◽

Cited By ~ 79

Author(s):

Sten Nilsson ◽

Lars Franzén ◽

Christopher Parker ◽

Christopher Tyrrell ◽

René Blom ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant Prostate Cancer ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant ◽

Radium 223

Download Full-text

Faculty Opinions recommendation of A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.3350956.3039058 ◽

2010 ◽

Author(s):

Yoshihiko Hirao ◽

Kiyohide Fujimoto

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Transdermal Estradiol ◽

Docetaxel Chemotherapy

Download Full-text

Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-12-2605 ◽

2012 ◽

Vol 19 (1) ◽

pp. 215-224 ◽

Cited By ~ 58

Author(s):

Charles J. Ryan ◽

Mark Rosenthal ◽

Siobhan Ng ◽

Joshi Alumkal ◽

Joel Picus ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Randomized Phase Ii ◽

Biomarker Analysis

Download Full-text

MP87-11 INTERIM ANALYSIS OF AN OPEN LABEL PHASE II STUDY OF ENZALUTAMIDE AND RADIUM RA 233 DICHLORIDE IN SYMPTOMATIC, METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS.

The Journal of Urology ◽

10.1016/j.juro.2018.02.2911 ◽

2018 ◽

Vol 199 (4S) ◽

Author(s):

Neal Shore ◽

Paul Schellhammer ◽

Ronald Tutrone ◽

Neil Mariados ◽

Stacey Harrelson

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Interim Analysis ◽

Phase Ii Study ◽

Castration Resistant Prostate Cancer ◽

Open Label ◽

Castration Resistant ◽

Open Label Phase

Download Full-text

TALAPRO-1: An open-label, response rate phase II study of talazoparib (TALA) in men with DNA damage repair defects (DDR) and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy (CT) and progressed on ≥ 1 novel hormonal therapy (NHT)

Annals of Oncology ◽

10.1093/annonc/mdy284.068 ◽

2018 ◽

Vol 29 ◽

pp. viii301

Author(s):

J.S. de Bono ◽

C. Higano ◽

F. Saad ◽

K. Miller ◽

M. Casey ◽

...

Keyword(s):

Prostate Cancer ◽

Dna Damage ◽

Phase Ii ◽

Hormonal Therapy ◽

Response Rate ◽

Phase Ii Study ◽

Castration Resistant Prostate Cancer ◽

Open Label ◽

Castration Resistant ◽

Damage Repair

Download Full-text

Phase II Study of Androgen Synthesis Inhibition with Ketoconazole, Hydrocortisone, and Dutasteride in Asymptomatic Castration-Resistant Prostate Cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-09-1722 ◽

2009 ◽

Vol 15 (22) ◽

pp. 7099-7105 ◽

Cited By ~ 52

Author(s):

Mary-Ellen Taplin ◽

Meredith M. Regan ◽

Yoo-Joung Ko ◽

Glenn J. Bubley ◽

Stephen E. Duggan ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant Prostate Cancer ◽

Synthesis Inhibition ◽

Androgen Synthesis ◽

Castration Resistant

Download Full-text

Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)

Investigational New Drugs ◽

10.1007/s10637-018-0630-9 ◽

2018 ◽

Vol 36 (5) ◽

pp. 919-926 ◽

Cited By ~ 1

Author(s):

Paul Monk ◽

Glenn Liu ◽

Walter M. Stadler ◽

Susan Geyer ◽

Ying Huang ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Controlled Study ◽

Castration Resistant Prostate Cancer ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant

Download Full-text